A phase III trial of AG10 in ATTR polyneuropathy
Phase of Trial: Phase III
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs AG 10 (Primary)
- Indications Amyloid polyneuropathy
- Focus Therapeutic Use
- Acronyms ATTRibute-PN
- Sponsors Eidos Therapeutics
- 31 Oct 2019 According to an Eidos Therapeutics media release, this study will commence in the first quarter of 2020.
- 30 Sep 2019 According to an Eidos Therapeutics media release, this study is planned to initiate by the end of 2019.
- 09 Sep 2019 According to an Alexion Pharmaceuticals media release, this study is planned to initiate in the second half of 2019.